Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations

• Published in: Frontiers in immunology Vol. 10; p. 3097
• Main Authors: Świerzko, Anna S, Michalski, Mateusz, Sokołowska, Anna, Nowicki, Mateusz, Szala-Poździej, Agnieszka, Eppa, Łukasz, Mitrus, Iwona, Szmigielska-Kapłon, Anna, Sobczyk-Kruszelnicka, Małgorzata, Michalak, Katarzyna, Gołos, Aleksandra, Wierzbowska, Agnieszka, Giebel, Sebastian, Jamroziak, Krzysztof, Kowalski, Marek L, Brzezińska, Olga, Thiel, Steffen, Matsushita, Misao, Jensenius, Jens C, Gajek, Gabriela, Cedzyński, Maciej
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 28.01.2020
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Combined Modality Therapy; complement; Disease Susceptibility; FCN1; FCN2; FCN3; Female; ficolin; Ficolins; Genetic Predisposition to Disease; Genotype; Hematologic Neoplasms - diagnosis; Hematologic Neoplasms - etiology; Hematologic Neoplasms - therapy; hematopoietic stem cell transplantation (HSCT); Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - methods; Humans; Immunology; Lectins - genetics; Lectins - metabolism; Male; Middle Aged; Multigene Family; Polymorphism, Single Nucleotide; Transplantation, Autologous; Treatment Outcome; FCN1; FCN2; FCN3; multiple myeloma; lymphoma; complement; ficolin; hematopoietic stem cell transplantation (HSCT)
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2019.03097

A prospective study of 312 patients [194 with multiple myeloma (MM) and 118 with lymphomas (LYMPH)] receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT) was conducted. Ficolins are innate immune defense factors, able to distinguish between "self" "abnormal self," and "non-self" and contribute to the elimination of the last two by direct opsonization and/or initiation of complement activation the lectin pathway. Concentrations of ficolin-1, ficolin-2, and ficolin-3 in serially taken serum samples were determined as were the polymorphisms of the corresponding ( , and ) genes. Serum samples were collected before conditioning chemotherapy, before HSCT, and once weekly post-HSCT (four to five samples in total); some patients were also sampled at 1 and/or 3 months post-transplantation. The control group (C) consisted of 267 healthy unrelated individuals. Median ficolin-1 and ficolin-2 (but not ficolin-3) levels in MM patients' sera taken before chemotherapy were lower (and correspondingly frequencies of the lowest concentrations were higher) compared with controls. That appeared to be associated with the malignant disease itself rather than with post-HSCT complications (febrile neutropenia, infections accompanied, or not with bacteremia). Higher frequencies of the genotype G/A-C/C-G/G (corresponding to polymorphisms at positions -542, -144, and +6658, respectively) and gene heterozygosity for the -857 C>A polymorphism were found among patients diagnosed with MM compared with the C group. Furthermore, G/G homozygosity (-557 A>G) was found more frequently and heterozygosity G/T at +6424 less frequently among LYMPH patients than among the healthy subjects. Heterozygosity for +1637delC mutation of the gene was more common among patients diagnosed with lymphomas who experienced hospital infections. Although no evidence for an association of low ficolin-1 or ficolin-2 with infections during neutropenia following chemotherapy before HSCT was found, we observed a possible protective effect of ficolins during follow-up.